Business Insider

New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment

REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...
Nasdaq

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast ...
Nasdaq

Genomic Health (GHDX) Oncotype DX Score Test Data Positive

Genomic Health, Inc.GHDX recently announced outcomes from 10 trials, which underscore the efficiency of the Oncotype DX Breast Recurrence Score test and Oncotype DX DCIS Score test for breast cancer.
Seeking Alpha

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
ascopubs.org

Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ

The Oncotype DX DCIS Score short form (DCIS Score) estimates the risk of an ipsilateral breast event (IBE) in patients with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery ...
Healio

Novel AI model improves recurrence risk stratification in breast cancer subset

An AI model significantly improved recurrence risk stratification vs. recurrence score among patients with hormone ...
News Medical

Oncotype DX Breast Recurrence Score test recommended by NICE for lymph node-positive breast cancer patients

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
Nature

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score

Breast cancer is the most common non-cutaneous cancer in women, and the second most frequent cause of cancer death among women. 1 Approximately 50% of breast cancer cases are estrogen receptor ...
Forbes

Oncotype Test Could Reduce Overtreatment Of Early Stage Breast Cancer

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. A key finding is that a low Oncotype DX DCIS Score™ conferred a low chance of ...
Nature

Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores

As FOXA1, GATA3, and ER coexist in a network regulating luminal subtype A breast carcinomas, we hypothesized that tumors expressing FOXA1 and/or GATA3 will have a low recurrence score. We therefore ...
The American Journal of Managed Care

Oncotype DX May Not Be Economical for Decisions on Adjuvant Radiation

A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS. A part of precision medicine involves ...